Lifitegrast sodium

CAS No. 1119276-80-0

Lifitegrast sodium( —— )

Catalog No. M35155 CAS No. 1119276-80-0

Lifitegrast sodium (SAR-1118-023 sodium) is a small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), which reduces inflammation of the ocular surface, and may be used in the study of dry eye.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 44 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Lifitegrast sodium
  • Note
    Research use only, not for human use.
  • Brief Description
    Lifitegrast sodium (SAR-1118-023 sodium) is a small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), which reduces inflammation of the ocular surface, and may be used in the study of dry eye.
  • Description
    Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease.
  • In Vitro
    Lifitegrast (SAR 1118) inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus lessening overall inflammatory responses.Lifitegrast strongly inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM.
  • In Vivo
    Lifitegrast has potent anti-inflammatory activity on corneal inflammation induced by antibiotic-killed P. aeruginosa and S. aureus in the presence of a silicone hydrogel lens with the optimal application being a 1% solution applied either 2 or 3 times prior.
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    Integrin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1119276-80-0
  • Formula Weight
    637.46
  • Molecular Formula
    C29H23Cl2N2NaO7S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : 100 mg/mL (156.87 mM; Ultrasonic)DMSO : 100 mg/mL (156.87 mM; Ultrasonic )
  • SMILES
    ClC1=C2C(CN(CC2)C(C3=CC=C(C=CO4)C4=C3)=O)=CC(Cl)=C1C(N[C@H](C([O-])=O)CC5=CC(S(C)(=O)=O)=CC=C5)=O.[Na+]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Perez VL, et al. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Apr;14(2):207-15.?
molnova catalog
related products
  • Abrilumab

    Abrilumab (MEDI-7183) is a fully human monoclonal antibody against α4β7 that inhibits the α4β7 integrin and can be used to study inflammatory bowel disease and ulcerative colitis.

  • αvβ1 integrin-IN-1

    αvβ1 integrin-IN-1 is a potent and selective inhibitor of αvβ1 integrin (IC50 of 0.63 nM) with antifibrotic effects.

  • Tadocizumab

    Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.